| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/28/2013 | US20130052152 Protective wound dressing device for oral and pharyngeal space |
| 02/28/2013 | US20130052145 Adhesive slow-release formulations for the local administration of curcumin |
| 02/28/2013 | US20130052142 Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
| 02/28/2013 | US20130052131 Nanoparticles, methods of making nanoparticles, and methods of use |
| 02/28/2013 | US20130052129 Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid |
| 02/28/2013 | DE4396086B3 Sirup mit N-Acetylcystein Syrup with N-acetylcysteine |
| 02/28/2013 | DE112011100657T5 Amin-polymere zur verwendung als gallensäuresequestriermittel Amine polymers for use as a bile acid sequestrant |
| 02/28/2013 | DE102011111944A1 Verwendung von Diclofenac zur Verhinderung und Behandlung grippaler Infekte sowie durch grippale Infekte bewirkter Krankheitssymtome Use of diclofenac for the prevention and treatment of influenza-like infections and bewirkter by influenza infections disease symptoms |
| 02/28/2013 | DE102011053068A1 Darreichungsform mit stabilisierten Wirkstoffpartikeln Dosage form stabilized drug particles |
| 02/28/2013 | CA2848896A1 Dyrk1 inhibitors and uses thereof |
| 02/28/2013 | CA2848726A1 Bax agonist, compositions, and methods related thereto |
| 02/28/2013 | CA2846611A1 Compositions and methods for treating neurodegenerative disease |
| 02/28/2013 | CA2846604A1 Compositions and methods for treating neurodegenerative disease |
| 02/28/2013 | CA2846507A1 Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4- tetrahydroisoquinoline-4-carboxamides for antimalarial therapies |
| 02/28/2013 | CA2846416A1 Tripartite bioactive composition providing anti-oxidant and anti-inflammatory effects with immune system and stem cell production enhancement |
| 02/28/2013 | CA2846348A1 Compositions and methods for treating viral diseases |
| 02/28/2013 | CA2846340A1 Treatment of symptoms associated with female gastroparesis |
| 02/28/2013 | CA2846231A1 Inhibitors of nedd8-activating enzyme |
| 02/28/2013 | CA2846204A1 Pyridazinone compounds and their use as daao inhibitors |
| 02/28/2013 | CA2846187A1 Pyrimido-pyridazinone compounds and use thereof |
| 02/28/2013 | CA2846183A1 Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
| 02/28/2013 | CA2846122A1 Radiolabeled compounds and their use as radiotracers for quantitative imaging of phosphodiesterase (pde10a) in mammals |
| 02/28/2013 | CA2846121A1 Hydrous adhesive skin patch |
| 02/28/2013 | CA2846046A1 Bicyclic heteroaromatic compounds |
| 02/28/2013 | CA2846011A1 (bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders |
| 02/28/2013 | CA2845829A1 Compositions and methods for use in promoting lean body mass |
| 02/28/2013 | CA2845756A1 Method of drug repositioning |
| 02/28/2013 | CA2845691A1 Liposome comprising at least one cholesterol derivative |
| 02/28/2013 | CA2845578A1 Pyrimidine pde10 inhibitors |
| 02/28/2013 | CA2845321A1 Combination treatments for hepatitis c |
| 02/28/2013 | CA2845275A1 Ophthalmic formulations |
| 02/28/2013 | CA2845258A1 Method for preparing metered dose sprayed inhaler for treating respiratory disease |
| 02/28/2013 | CA2845149A1 Pyrano [3,2-d][1,3] thiazole as glycosidase inhibitors |
| 02/28/2013 | CA2845093A1 2 -amino-4 - (pyridin- 2 -yl) - 5, 6 -dihydro-4h- 1, 3 -oxazine derivatives and their use as bace-1 and/or bace - 2 inhibitors |
| 02/28/2013 | CA2844988A1 2-spiro-substituted iminothiazines and their mono- and dioxides as bace inhibitors, compositions, and their use |
| 02/28/2013 | CA2844812A1 Meta-substituted biphenyl peripherally restricted faah inhibitors |
| 02/28/2013 | CA2844809A1 Combination cancer therapy of hsp90 inhibitor with antimetabolite |
| 02/28/2013 | CA2844775A1 Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients |
| 02/28/2013 | CA2844764A1 1,4-diazabicyclo[3.2.2]nonanes as neuronal nicotinic acetylcholine receptor ligands |
| 02/28/2013 | CA2844729A1 Serine/threonine pak1 inhibitors |
| 02/28/2013 | CA2844388A1 Process and intermediates for preparing macrolactams |
| 02/28/2013 | CA2844310A1 Inhibitors of the renal outer medullary potassium channel |
| 02/28/2013 | CA2844086A1 Benzofuran compounds for the treatment of hepatitis c virus infections |
| 02/28/2013 | CA2751218A1 Weight loss formulation |
| 02/27/2013 | EP2562257A1 Method for stabilizing functional nucleic acids |
| 02/27/2013 | EP2562177A2 Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof |
| 02/27/2013 | EP2562176A1 Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same |
| 02/27/2013 | EP2562172A1 Sphaelactone derivatives, their pharmaceutical compositions, preparation methods and uses |
| 02/27/2013 | EP2562168A1 Therapeutic piperazines as PDE4 inhibitors |
| 02/27/2013 | EP2562160A1 Therapeutic agent or preventive agent for urine collection disorder |
| 02/27/2013 | EP2562159A1 Preparation method of fluoro-substituted deuterated diphenylurea |
| 02/27/2013 | EP2562157A1 Heteroaryl (alkyl) dithiocarbamate compounds, preparation methods and uses thereof |
| 02/27/2013 | EP2562156A2 Colchicine derivatives or pharmaceutically acceptable salts thereof, method for preparing said derivatives, and pharmaceutical composition comprising said derivatives |
| 02/27/2013 | EP2562155A1 Novel hydroxamic acid derivative |
| 02/27/2013 | EP2561889A2 Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
| 02/27/2013 | EP2561887A2 Cancer therapy sensitizer |
| 02/27/2013 | EP2561879A1 Macrophage activating factor for use in the treatment of chronic fatigue syndrome (CFS) and CFS-related diseases and disorders |
| 02/27/2013 | EP2561877A1 A Composition containing a Bisphosphonic Acid in combination with Vitamin D |
| 02/27/2013 | EP2561876A1 Formulations of Deoxycholic Acid and Salts Thereof |
| 02/27/2013 | EP2561875A2 Inhibitors of bruton's tyrosine kinase |
| 02/27/2013 | EP2561874A2 Pharmaceutical compositions for treating cancer |
| 02/27/2013 | EP2561873A1 Structural mimetics of proline-rich peptides and use of same |
| 02/27/2013 | EP2561872A1 3, 5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo [4,5-d]pyrimidin-2-one compounds and prodrugs thereof |
| 02/27/2013 | EP2561871A1 Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer |
| 02/27/2013 | EP2561870A1 Kappa-Opiate Agonists For The Treatment Of Diarrhea-Predominant and Alternating Irritable Bowel Syndrome |
| 02/27/2013 | EP2561869A1 Skin collagen production promoter |
| 02/27/2013 | EP2561868A1 Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field |
| 02/27/2013 | EP2561867A1 CDK9 inhibitors in the treatment of midline carcinoma |
| 02/27/2013 | EP2561866A1 Morphinan-derivatives for treating diabetes and related disorders |
| 02/27/2013 | EP2561865A2 Transdermal absorption preparation |
| 02/27/2013 | EP2561864A1 Coated tablet comprising tianeptine and process for preparation thereof |
| 02/27/2013 | EP2561863A1 Pharmaceutical compositions comprising voriconazole |
| 02/27/2013 | EP2561862A1 Vesicle-containing composition |
| 02/27/2013 | EP2561861A1 Water-soluble pharmaceutical composition comprising at least one therapeutically active substance having hydrophobic properties and at least one compound selected from among sialoglycosphingolipids, glycosphingolipids or a mixture of sialoglycosphingolipids and glycosphingolipids |
| 02/27/2013 | EP2561860A1 Implantable polymeric device for sustained release of buprenorphine |
| 02/27/2013 | EP2561767A1 Epicatechin for alleviating symptoms of allergy |
| 02/27/2013 | EP2561079A1 Lipid binding nucleic acids |
| 02/27/2013 | EP2561078A2 NOVEL STRUCTURALLY DESIGNED shRNAs |
| 02/27/2013 | EP2561069A2 Lysosomal storage disease enzyme |
| 02/27/2013 | EP2560981A2 Synthetic oligosaccharides for staphylococcus vaccine |
| 02/27/2013 | EP2560980A2 Osmium (ii) arene azo anti-cancer complexes |
| 02/27/2013 | EP2560978A1 Inhibitors of arginase and their therapeutic applications |
| 02/27/2013 | EP2560977A1 New ag(i) compounds with chelating ligands and their use in pharmaceutical compositions |
| 02/27/2013 | EP2560976A1 Furopyridine compounds and uses thereof |
| 02/27/2013 | EP2560975A1 Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes as vasopressin v1a receptor antagonists |
| 02/27/2013 | EP2560974A1 Pyrrazolopyridine derivatives |
| 02/27/2013 | EP2560973A1 Modulators of 5-ht receptors and methods of use thereof |
| 02/27/2013 | EP2560972A2 Compounds and methods for kinase modulation, and indications therefor |
| 02/27/2013 | EP2560971A1 Pyrrolopyridine inhibitors of kinases |
| 02/27/2013 | EP2560970A1 NOVEL INTERMEDIATES FOR THE PREPARATION OF HMG-CoA REDUCTASE INHIBITORS |
| 02/27/2013 | EP2560969A1 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists |
| 02/27/2013 | EP2560967A1 Heterocyclic carboxylic acid amides as pdk1 inihibitors |
| 02/27/2013 | EP2560966A2 Multisubstituted aromatic compounds as inhibitors of thrombin |
| 02/27/2013 | EP2560963A1 Derivatives of nitrogen heterocycles, method for preparing same and use thereof in human therapy |
| 02/27/2013 | EP2560962A1 Indazole compounds useful as ketohexokinase inhibitors |
| 02/27/2013 | EP2560955A2 Novel benzamide derivatives |
| 02/27/2013 | EP2560953A2 Novel inhibitors |
| 02/27/2013 | EP2560951A1 Production of atorvastatin low in ether impurities |
| 02/27/2013 | EP2560949A1 Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2 |
| 02/27/2013 | EP2560947A1 Lysine specific demethylase-1 inhibitors and their use |